文献速递心脑血管急症重症综合管理与镇静镇痛

甘露醇有效降低颅内高压的证据:个体患者数据Meta分析

Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis.
PubMed 文献 · Neurocrit Care · 2020-01-01
一句话结论个体患者数据Meta分析显示,甘露醇可显著降低成人脑损伤患者的颅内压,降幅与基线颅内压成比例,每升高1 mmHg基线值多降0.64 mmHg。

本研究旨在通过个体患者数据(IPD)Meta分析评估甘露醇降低成人脑损伤患者颅内压的有效性及其与基线颅内压值的相关性,并与同一批研究的聚合数据(AD)Meta分析结果比较。检索Medline至2019年3月1日,纳入有IPD的自身前后对照研究,对象为创伤性脑出血、蛛网膜下腔出血或出血性/缺血性卒中并因颅内高压接受甘露醇治疗的成人患者。共7项研究提供98例患者的IPD。线性混合效应模型显示,甘露醇给药后颅内压从基线平均22.1 mmHg显著降至60、120、180分钟时的16.8、12.8、9.7 mmHg;颅内压降幅与基线值成比例,基线颅内压每增加1 mmHg,降幅增加0.64 mmHg;剂量不影响颅内压降幅。AD Meta分析(基于给药后30-60分钟数据、未考虑多时间点测量)高估了颅内压降幅(10 mmHg),而Meta回归结果相似(基线每增加1 mmHg降幅增加0.66 mmHg)。作者结论:甘露醇能有效降低病理性颅内压,降幅与颅内高压程度成比例;IPD Meta分析比AD方法能更精确地量化颅内压变化。

要点

  • 成人脑损伤(创伤性脑出血、蛛网膜下腔出血、出血性/缺血性卒中)患者接受甘露醇后,颅内压从基线平均22.1 mmHg降至60分钟16.8 mmHg、120分钟12.8 mmHg、180分钟9.7 mmHg。
  • 颅内压降幅与基线值成比例:基线颅内压每增加1 mmHg,降幅增加0.64 mmHg。
  • 甘露醇剂量不影响颅内压降幅。
  • AD Meta分析基于给药后30-60分钟数据且未考虑多时间点测量,高估颅内压降幅达10 mmHg;Meta回归显示基线每增加1 mmHg降幅增加0.66 mmHg。
  • IPD Meta分析较AD方法能更精确地量化颅内压变化。

适用人群与场景

  • 成人创伤性脑出血、蛛网膜下腔出血或出血性/缺血性卒中患者,因颅内高压接受甘露醇治疗。
  • 研究纳入有个体患者数据、自身前后对照设计的研究。

处置流程与药物剂量

  • 甘露醇用于降低病理性颅内压,剂量不影响颅内压降幅(原文未给出具体剂量方案)。

研究设计与关键结果

  • 个体患者数据Meta分析纳入7项研究共98例患者,线性混合效应模型显示甘露醇给药后颅内压从基线平均22.1 mmHg显著降至60分钟16.8 mmHg、120分钟12.8 mmHg、180分钟9.7 mmHg。
  • 颅内压降幅与基线值成比例:基线颅内压每增加1 mmHg,降幅增加0.64 mmHg;剂量不影响颅内压降幅。
  • 聚合数据Meta分析基于给药后30-60分钟数据且未考虑多时间点测量,高估颅内压降幅(10 mmHg);Meta回归显示基线每增加1 mmHg降幅增加0.66 mmHg。

证据类型、等级与局限

  • 证据类型:个体患者数据Meta分析(自身前后对照研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为甘露醇能有效降低病理性颅内压,降幅与颅内高压程度成比例。
  • 作者认为IPD Meta分析比AD方法能更精确地量化颅内压变化。
  • 原文未据此给出推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Mannitol is currently used to reduce intracranial pressure (ICP), but the evidence supporting its usefulness has been questioned. We aim to meta-analyze the effectiveness of mannitol in reducing ICP in adult patients with cerebral injuries and its dependency on baseline ICP values, comparing findings from individual patient data (IPD) and aggregated data (AD) meta-analysis performed on the same studies. We searched the Medline database, with no time limitation, through March 1, 2019. We selected studies for which IPD were available, with a before-after design, concerning adult patients with traumatic cerebral hemorrhages, subarachnoid hemorrhages, or hemorrhagic and ischemic stroke, treated with mannitol for increased intracranial hypertension. We extracted ICP values at baseline and at different time-points, and mannitol doses. We used a multilevel approach to account for multiple measurements on the same patient and for center variability. The AD meta-analysis and meta-regression were conducted using random-effects models. Three studies published IPD, and four authors shared their datasets. Two authors did not own their datasets anymore. Eight authors were unreachable, while 14 did not answer to our request. Overall, 7 studies provided IPD for 98 patients. The linear mixed-effects model showed that ICP decreased significantly after mannitol administration from an average baseline value of 22.1 mmHg to 16.8, 12.8, and 9.7 mmHg at 60, 120, and 180 min after mannitol administration. ICP reduction was proportional to baseline values with a 0.64 mmHg decrease for each unitary increment of the initial ICP value. Dose did not influence ICP reduction. The AD meta-analysis, based on data collected between 30 and 60 min from mannitol administration not accounting for multiple time-point measurements, overestimated ICP reduction (10 mmHg), while meta-regression provided similar results (0.66 mmHg decrease for each unitary increase of initial ICP). Mannitol is effective in reducing pathological ICP, proportionally to the degree of intracranial hypertension. IPD meta-analysis provided a more precise quantification of ICP variation than the AD approach.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Poole D, Citerio G, Helbok R, et al. Evidence for Mannitol as an Effective Agent Against Intracranial Hypertension: An Individual Patient Data Meta-analysis. Neurocrit Care. 2020. PMID: 31264071. doi:10.1007/s12028-019-00771-y

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。